Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer
December 04 2017 - 8:30AM
Novelion Therapeutics Inc. (NASDAQ:NVLN), a
biopharmaceutical company dedicated to developing new standards of
care for individuals living with rare metabolic diseases,
today announced the appointment of Michael Price
as senior vice president and chief financial officer
(CFO), effective December 4, 2017. Gregory Perry has
resigned as CFO of Novelion to pursue other
opportunities, and will remain with the Company until December 31,
2017 to enable an effective transition.
Chairman of the Board
of Directors Jason Aryeh said, “We are
very pleased to welcome Michael, a skilled executive with deep
financial acumen, and extensive experience in organizations
with both research and development and global commercial
capabilities. We look forward to his contributions as we focus on
maximizing the value and growth potential of
our current product portfolio and creating the
ability to invest in our growth. With a new leadership
team that includes the recent additions of Chief Operating Officer
Jeffrey Hackman and Head of Research and Development Murray
Stewart, we believe we are well positioned to execute on these
goals.
“Also, we would like to recognize Greg’s
leadership, and the significant progress we made during his tenure
as CFO to stabilize and cleanse many of the issues inherited in
2015. Thanks in large part to those accomplishments, we believe
meaningful value creation opportunities are ahead.”
Michael Price was most recently vice president
and chief financial officer for Noven Pharmaceuticals, Inc., a
NASDAQ-listed company until its acquisition by Hisamitsu
Pharmaceutical Company. Noven Pharmaceuticals, Inc. is a specialty
pharmaceutical company engaged in the research, development,
manufacturing, marketing and sale of prescription pharmaceutical
products. In his role at Noven, Mr. Price was directly involved
with the development and execution of strategy that scaled the
Company’s commercial organization and significantly increased
revenues. Prior to Noven, Mr. Price was vice president, chief
financial officer, treasurer, secretary and a member of the board
of directors for Bentley Pharmaceuticals, a New York Stock
Exchange-listed company until Teva Pharmaceutical Industries’ 2008
acquisition. Mr. Price is a certified public accountant. He holds a
bachelor of science degree in business administration (accounting)
from Auburn University and a master of business administration
degree from Florida State University.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical
company dedicated to developing new standards of care for
individuals living with rare diseases. Novelion has a diversified
commercial portfolio through its indirect subsidiary, Aegerion
Pharmaceuticals, Inc., which includes JUXTAPID® and MYALEPT®, and
is also developing zuretinol acetate for the potential treatment of
inherited retinal disease caused by underlying mutations in RPE65
or LRAT genes. The company seeks to advance its portfolio of rare
disease therapies by investing in science and clinical
development.
Forward Looking Statements
Certain statements in this press release
constitute "forward-looking statements" of Novelion within the
meaning of applicable laws and regulations and constitute
"forward-looking information" within the meaning of applicable
Canadian securities laws. Any statements contained herein
which do not describe historical facts, including statements
regarding the contributions of Mr. Price and Mr. Perry to our
business and Novelion’s goals and pipeline potential and beliefs
about our ability to maximize the value of our marketed therapies
and Novelion’s potential growth, are forward-looking statements
which involve risks and uncertainties that could cause actual
results to differ materially from those discussed in such
forward-looking statements. Such risks and uncertainties
include, among others, those risks identified in Novelion’s filings
with the U.S. Securities and Exchange Commission (the “SEC”),
including under the heading "Risk Factors" in Novelion's Annual
Report on Form 10-K filed on March 30, 2017, Novelion’s Quarterly
Report on Form 10-Q filed on November 9, 2017, and subsequent
filings, with the SEC, available on the SEC's website at
www.sec.gov. Any such risks and uncertainties could materially and
adversely affect Novelion’s results of operations, its
profitability and its cash flows, which would, in turn, have a
significant and adverse impact on Novelion’s stock price. We
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made.
Except as required by law, we undertake no obligation to update or
revise the information contained in this press release, whether as
a result of new information, future events or circumstances or
otherwise.
Investors and others should note that we
communicate with our investors and the public using our company
website www.novelion.com, including, but not limited to, company
disclosures, investor presentations and FAQs, SEC filings, press
releases, public conference calls transcripts and webcast
transcripts. The information that we post on these websites could
be deemed to be material information. As a result, we encourage
investors, the media and others interested to review the
information that we post there on a regular basis. The contents of
our website shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate
CommunicationsNovelion
Therapeutics857-242-5024amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Sep 2023 to Sep 2024